Jeffrey Quinn

Jeffrey Quinn has a diverse work experience in the fields of functional genomics, gene editing, and biomedical research. Jeffrey is currently working as the Associate Director of Off-Target Biology at Beam Therapeutics since November 2022. Prior to that, they held positions at Inscripta, Inc. as a Senior Scientist II in Functional Genomics & Gene Editing from September 2021 to October 2022, and as a Senior Scientist I in Mammalian High-Throughput Screening & Automation from September 2020 to September 2021.

Before joining Inscripta, Inc., Jeffrey worked as a Postdoctoral Fellow in the Lab of Dr. Jonathan Weissman at UCSF from May 2016 to September 2020. In this role, they developed CRISPR/Cas9-based technologies for single-cell lineage tracing and genome editing, and applied advanced functional genomics techniques.

Jeffrey's educational background includes a doctoral program at Stanford University, where they worked as a Doctoral Student in the Lab of Dr. Howard Chang from September 2010 to April 2016. During this time, they developed and applied biochemical, computational, and functional genomics tools for studying long noncoding RNAs (lncRNAs) interactions, structure, function, and evolution. Jeffrey published multiple first-author research papers, reviews, and articles in renowned scientific journals.

Additionally, Jeffrey gained research experience as a Research Intern at Biogen Idec in May 2010.

Jeffrey Quinn earned a Bachelor of Science (B.S.) in Bioengineering and Biomedical Engineering from the Massachusetts Institute of Technology in 2010. Jeffrey then pursued further studies at Stanford University, where they obtained a Master of Science (M.S.) in Bioengineering and Biomedical Engineering in 2016. Additionally, Jeffrey Quinn earned a Doctor of Philosophy (Ph.D.) in Bioengineering and Biomedical Engineering from Stanford University in 2016 as well.